ScripSanofi’s hopes that itepekimab will follow Dupixent onto the list of approved drugs for chronic obstructive pulmonary disease (COPD) have been hit by a mixed set of results from a pair of late-stage t
Pink SheetEngland’s health technology assessment (HTA) institute, NICE, has recommended in favor of making Pfizer’s Hympavzi (marstacimab) available on the National Health Service for preventing severe hemophil
ScripUS/Swiss biotech GlycoEra AG announced a $130m series B financing on 27 May that it says will enable it to advance its first protein-degradation drug candidate through Phase II proof of concept as pre
Pink SheetFour drugs with an orphan designation – Aucatzyl (obecabtagene autoleucel), Blenrep (belantamab mafodotin), Ezmekly (mirdametinib) and Maapliv (amino acids) – are among the 10 new products on track fo